🔗 Share this article

As America continues making unprecedented adjustments to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus shots during the global health crisis and has zeroed in on possible deaths after COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities had intended to unveil radical changes to the childhood vaccination calendar recently, bringing the US with the Danish vaccine program, sources say – a substantial departure that would place the US out of step with a large portion of the world with no evidence for public health gain. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has frequently advocated for ending specific pediatric shot schedules in the US so as to align more in line with the Danish model, a country with nationalized medicine and a population about the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

The appointee has no obvious background in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in leading a large organization. She is not an expert in drug approvals.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

This division has an immense workload at the FDA, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the generic program clears a multitude of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and all of those must be looked after,” she noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the job, which supervises over 5,000 staff members. “It’s a huge management job, if you execute it properly,” she said.

Response and Controversial Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “concerns are based on flawed presumptions”.

“This background matches the responsibilities of her job,” the spokesperson stated, noting the period Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed one-day therapy clearance system that reportedly troubled her former heads. “How are these medications being picked for this voucher program? Who makes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, with the exception of shots.”

Established History on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, past, some experts said. She published a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the current administration featured altering guidelines for new vaccines and halting “non-essential” vaccines, she said after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who commences with her preconceived notions and tailors the evidence to fit the science in a very misleading, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|